Valued Members,
Are you ready for another strong performer?
Our selection for this quarter is Nutranomics, Inc. (NNRX), a company reconciling the gap between science and nature, while driving revenue growth in the process. Unlike so many biotech plays, NNRX is already reporting revenue. In fact, NNRX surpassed $5.6M in sales over the past two years, has products on shelves and is making headway into large distribution networks.
We are proud to be introducing this company to our valued subscribers below a $70M valuation, especially when we look to the upside available.
A Healthy Play: NNRX
One of the best ways to familiarize yourself is to watch one of the many lectures, interviews and presentations with Nutranomics' current CEO, Dr. Tracy Gibbs.
In one presentation, Dr. Gibbs gave a profound definition of health, in contrast to what so often comes to mind. (Paraphrased:) "Health is not simply the absence of disease, but a state of well-being. Health is being able to come home from a full day's work and still have an abundance of vitality, the energy to give your children the attention they deserve, take time for yourself, your hobbies and treat your significant other. Health is being able to put in a full 18 hours and still be able to sleep well at night."
Nutranomics is about creating products so everyone can be healthy. Everyone should be able to spend time with their friends and family, enjoy an abundance of life – and not be subject to premature disease or health problems.
Closing the Gap: Nature's Science
Nutranomics is natural health without the quackery. All of its facilities are cGMP Compliant and FDA Approved. Nutranomics provides dietary supplements and the company does not make unsubstantiated claims. The products offered are not intended to diagnose, treat, cure, or prevent any disease. Rather, the products are offered to help promote a healthy lifestyle. As it turns out, consumers (and the FDA) appreciate this honesty and the revenue numbers speak for themselves.
Instead of pseudoscience, Nutranomics focuses on evidence and clinical trials.
In a message to its base last Friday, Nutranomics outlined its focus on growing the company and building upon the foundation established over the last seventeen years. "We believe that we are on the verge of an exciting period growth and development," commented Tracy Gibbs, Nutranomics' CEO. Given its tremendous success in the public arena thus far, we tend to agree with this assessment.
Predicting Going Forward
We speculate that Nutranomics will look to leverage its growing valuation to shore up its cash position and potentially focus on pursuing Phase I, II and III clinical trials for select products in its portfolio (currently over 850 nutritional food and supplement formulas including already patented AES® technology). We believe this may have been a driving factor toward Nutranomics push to go public and hint at a much larger picture ahead.
We must disclaim that this is purely speculative and conjecture based on several assumptions – there is no way to conclusively determine the true intention or inner workings of the company at this stage.
However, we are comfortable with the current company's valuation and historical performance and see tremendous upside regardless of the clinical trial route. Further, we have historically observed a pattern of companies going public to take on larger markets and we believe this makes a realistic case for Nutranomics announcing a large undertaking and significant catalyst event shortly.
Conclusion
All in all, we believe we have found the next top performer as it begins to take off. NNRX's performance to date demonstrates growing interest, with Friday closing up 6.72% at $1.43. This next week could present an ideal entry opportunity for our subscriber base below the $2.00 mark. At its current rate, momentum and technicals point to a much more expensive November for NNRX.
Remember – all of the above information is just that, information. It represents our opinion only. Please use this as a starting point for your own due diligence. Come to your own conclusions about NNRX and where you believe it will go. For us, we believe the facts will speak for themselves.
Sincerely,
Newsletter Team
Research Department
Investors Alliance
